Capricor Therapeutics (CAPR) Return on Capital Employed: 2012-2025
Historic Return on Capital Employed for Capricor Therapeutics (CAPR) over the last 12 years, with Sep 2025 value amounting to -0.71%.
- Capricor Therapeutics' Return on Capital Employed rose 9.00% to -0.71% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.71%, marking a year-over-year increase of 9.00%. This contributed to the annual value of -0.45% for FY2024, which is 59.00% up from last year.
- Per Capricor Therapeutics' latest filing, its Return on Capital Employed stood at -0.71% for Q3 2025, which was down 42.20% from -0.50% recorded in Q2 2025.
- Capricor Therapeutics' 5-year Return on Capital Employed high stood at -0.38% for Q4 2024, and its period low was -3.57% during Q3 2023.
- In the last 3 years, Capricor Therapeutics' Return on Capital Employed had a median value of -1.17% in 2024 and averaged -1.38%.
- In the last 5 years, Capricor Therapeutics' Return on Capital Employed tumbled by 289bps in 2023 and then surged by 277bps in 2024.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Return on Capital Employed stood at -0.55% in 2021, then crashed by 34bps to -0.89% in 2022, then slumped by 56bps to -1.44% in 2023, then spiked by 106bps to -0.38% in 2024, then increased by 9bps to -0.71% in 2025.
- Its Return on Capital Employed stands at -0.71% for Q3 2025, versus -0.50% for Q2 2025 and -0.38% for Q4 2024.